You are here

Article metrics

Article menu
XML
Multiple sclerosis
Research paper
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

 

Online download statistics by month:

Online download statistics by month: February 2014 to April 2023

AbstractFullPdf
Feb 2014549395236
Mar 2014384431238
Apr 2014166190161
May 2014107144125
Jun 20145312398
Jul 20145811978
Aug 20147511081
Sep 201454132111
Oct 2014998230228
Nov 2014983185230
Dec 20143188984
Jan 20151938364
Feb 201515411961
Mar 201516410551
Apr 201517411586
May 20156913753
Jun 2015968352
Jul 2015699246
Aug 2015497649
Sep 2015678051
Oct 2015395942
Nov 20156413289
Dec 2015527329
Jan 2016596657
Feb 2016535945
Mar 2016517366
Apr 2016756863
May 2016336157
Jun 2016355148
Jul 2016386534
Aug 2016455032
Sep 2016544233
Oct 2016639060
Nov 2016365348
Dec 2016266052
Jan 2017426656
Feb 2017193036
Mar 201793425
Apr 201795220
May 2017167740
Jun 2017225724
Jul 2017504628
Aug 2017473822
Sep 2017927232
Oct 2017855545
Nov 2017948048
Dec 2017493930
Jan 2018896531
Feb 2018554526
Mar 2018795732
Apr 2018605134
May 2018937528
Jun 2018706630
Jul 2018634145
Aug 2018615542
Sep 2018817140
Oct 20181099730
Nov 201811610259
Dec 2018626143
Jan 2019928441
Feb 2019706141
Mar 2019524644
Apr 2019625741
May 2019826265
Jun 2019625564
Jul 2019686261
Aug 2019514537
Sep 2019523935
Oct 2019866434
Nov 2019855247
Dec 2019655438
Jan 2020503842
Feb 2020555043
Mar 2020665934
Apr 2020625951
May 2020785433
Jun 2020797517
Jul 2020524630
Aug 2020474618
Sep 2020867421
Oct 2020776430
Nov 2020765918
Dec 2020846526
Jan 2021634818
Feb 2021635927
Mar 2021756523
Apr 2021957731
May 2021937647
Jun 2021535324
Jul 2021626230
Aug 2021636219
Sep 2021545421
Oct 2021787251
Nov 2021704829
Dec 2021554714
Jan 2022898318
Feb 202218713733
Mar 202214314321
Apr 20221119923
May 202214613232
Jun 202215313930
Jul 20221289518
Aug 20221081038
Sep 202211211118
Oct 202214412529
Nov 20221079723
Dec 2022827018
Jan 202311910622
Feb 202313210836
Mar 202313112225
Apr 2023807531
Total1141093105414